These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. Kiska DL; Kerr A; Jones MC; Caracciolo JA; Eskridge B; Jordan M; Miller S; Hughes D; King N; Gilligan PH J Clin Microbiol; 1996 Apr; 34(4):886-91. PubMed ID: 8815102 [TBL] [Abstract][Full Text] [Related]
23. Preventing Burkholderia cepacia complex infection in cystic fibrosis: is there a middle ground? Lipuma JJ J Pediatr; 2002 Oct; 141(4):467-9. PubMed ID: 12378182 [No Abstract] [Full Text] [Related]
24. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Bernhardt SA; Spilker T; Coffey T; LiPuma JJ Clin Infect Dis; 2003 Sep; 37(6):780-5. PubMed ID: 12955638 [TBL] [Abstract][Full Text] [Related]
25. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Burdge DR; Nakielna EM; Noble MA Infect Control Hosp Epidemiol; 1993 Mar; 14(3):127-30. PubMed ID: 7683031 [TBL] [Abstract][Full Text] [Related]
26. [Molecular typing by pulsed field gel electrophoresis of Pseudomonas (Burkholderia) cepacia isolated from a nosocomial infection]. Rodriguez P; Fourmaux S; de Barbeyrac B; Rogues AM; Parneix P; Leger A; Bebear C Pathol Biol (Paris); 1995 Apr; 43(4):352-7. PubMed ID: 7567128 [TBL] [Abstract][Full Text] [Related]
27. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? Butler SL; Doherty CJ; Hughes JE; Nelson JW; Govan JR J Clin Microbiol; 1995 Apr; 33(4):1001-4. PubMed ID: 7540623 [TBL] [Abstract][Full Text] [Related]
28. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Humphreys H; Peckham D; Patel P; Knox A Thorax; 1994 Nov; 49(11):1157-9. PubMed ID: 7530384 [TBL] [Abstract][Full Text] [Related]
29. Low incidence of pulmonary Pseudomonas cepacia infection in Danish cystic fibrosis patients. Nir M; Johansen HK; Høiby N Acta Paediatr; 1992 Dec; 81(12):1042-3. PubMed ID: 1283959 [No Abstract] [Full Text] [Related]
30. [Burkholderia cepacia: dangers of a phytopathogen organism for patients with cystic fibrosis]. Segonds C; Chabanon G Ann Biol Clin (Paris); 2001; 59(3):259-69. PubMed ID: 11397673 [TBL] [Abstract][Full Text] [Related]
31. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex. Govan JR J R Soc Med; 2000; 93 Suppl 38(Suppl 38):40-5. PubMed ID: 10911818 [No Abstract] [Full Text] [Related]
32. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Mahenthiralingam E; Vandamme P; Campbell ME; Henry DA; Gravelle AM; Wong LT; Davidson AG; Wilcox PG; Nakielna B; Speert DP Clin Infect Dis; 2001 Nov; 33(9):1469-75. PubMed ID: 11588691 [TBL] [Abstract][Full Text] [Related]
33. Burkholderia cenocepacia, B. multivorans, B. ambifaria and B. vietnamiensis isolates from cystic fibrosis patients have different profiles of exoenzyme production. Carvalho AP; Ventura GM; Pereira CB; Leão RS; Folescu TW; Higa L; Teixeira LM; Plotkowski MC; Merquior VL; Albano RM; Marques EA APMIS; 2007 Apr; 115(4):311-8. PubMed ID: 17504297 [TBL] [Abstract][Full Text] [Related]
34. Pseudomonas (Burkholderia) cepacia in children with cystic fibrosis: epidemiological investigation by analysis or restriction fragment length polymorphism. Valcin M; Moissenet D; Sardet A; Tournier G; Garbarg-Chenon A; Vu-Thien H Pathol Biol (Paris); 1996 May; 44(5):442-6. PubMed ID: 8758491 [TBL] [Abstract][Full Text] [Related]
35. Dental units as infection sources of Pseudomonas aeruginosa. Barben J; Schmid J Eur Respir J; 2008 Oct; 32(4):1122-3. PubMed ID: 18827162 [No Abstract] [Full Text] [Related]
36. Predictors of mortality in adults with cystic fibrosis. Courtney JM; Bradley J; Mccaughan J; O'Connor TM; Shortt C; Bredin CP; Bradbury I; Elborn JS Pediatr Pulmonol; 2007 Jun; 42(6):525-32. PubMed ID: 17469153 [TBL] [Abstract][Full Text] [Related]
37. Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. Geisenberger O; Givskov M; Riedel K; Høiby N; Tümmler B; Eberl L FEMS Microbiol Lett; 2000 Mar; 184(2):273-8. PubMed ID: 10713433 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Traczewski MM; Brown SD Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756 [TBL] [Abstract][Full Text] [Related]
39. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Burdge DR; Noble MA; Campbell ME; Krell VL; Speert DP Clin Infect Dis; 1995 Feb; 20(2):445-8. PubMed ID: 7537977 [TBL] [Abstract][Full Text] [Related]
40. Fatal sepsis due to Pseudomonas cepacia. Saha SK; Hanif M; Khan WA; Rahaman D; Khan N; Hoq MS; Sarwardi G Singapore Med J; 1994 Oct; 35(5):475-6. PubMed ID: 7535478 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]